Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


While Navigating Risks, WuXi To Benefit from Global Outsourcing

This article was originally published in PharmAsia News

Executive Summary

BEIJING - WuXi PharmaTech is positioning itself to ride the rising tides of global pharmaceutical outsourcing to strengthen its role as China's largest contract research organization, according to a WuXi executive and an independent analyst

You may also be interested in...

Patheon Looks To Establish Stronger Ties with Japanese Pharmas

TOKYO - Toronto-based drug maker and developer Patheon created subsidiary Patheon K.K. in Tokyo this month in hopes of securing stronger ties with Japanese pharmaceutical companies

PharmAsia News Notable Notes: WuXi Confronts Chinese Macro Challenges

WuXi Pharma has systems in place to soften the impact of cost inflation issues expected to impact the Chinese pharma industry, according to Oppenheimer analyst Charles Rhyee

Insider Analysis From Jones Day: New Patent Approach Is Needed For Pharmaceutical Research In China

By Steven X. Cui, Ph.D., Jones Day, Beijing, and Tony Chen, Jones Day, Shanghai

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts